Abstracts

Protease Inhibitors to Treat Hepatitis C in the Swiss HIV Cohort Study: High Efficacy But Low Uptake

Background: Combination therapy with pegylated interferon, ribavirin and protease inhibitors (PI) has become the standard of care for chronic hepatitis C virus (HCV) genotype 1 infection. However, there is limited information on treatment outcomes in HIV/HCV coinfected patients in clinical routine settings. We assessed PI treatment uptake and efficacy in the Swiss HIV Cohort Study…

Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort

Background: Clinical trials on triple therapy against HCV infection including telaprevir (TVR) or boceprevir (BOC) plus pegylated interferon and ribavirin (PR) have reported considerably higher response rates than with PR alone. However, there is little information about the response to triple therapy used in clinical practice in these patients. This study was aimed to evaluate…

Telaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TelapreVIH)

Background: Retreatment with PegInterferon (PegIFN) + Ribavirin (RBV) results in poor SVR rates in HIV-HCV coinfected patients. There is no data regarding the use of Telaprevir (TVR) + PegIFN-RBV in this population Methodology: HIV-1 infected patients who had previously failed ≥12 weeks PegIFN-RBV for HCV genotype 1 coinfection were enrolled in a single-arm, phase 2…

Favorable Adverse Event Profile of Sofosbuvir/Ribavirin Versus Standard of Care for Hepatitis C

Background: The treatment of Hepatitis C virus (HCV) infection is rapidly evolving from the current standard of care comprised of interferon (IFN)-based triple therapy to IFN free treatment with directly acting antiviral agents (DAAs). Triple therapy with Boceprevir (BOC) or Telaprevir has resulted in improved SVR rates, however adverse events (AEs), pill burden and drug…

Slow HCV-RNA decay and early resistance predict the risk of failure to TVR/BOC treatment

Background: Triple therapy with telaprevir (TVR)/boceprevir (BOC)+peg-IFN+RBV can achieve excellent results in terms of antiviral efficacy, but it can be burdened by failures with the development of resistance mutations (RAVs). Aim of this study was to evaluate, in clinical practice, the kinetics of HCV-RNA decay and the early appearance of RAVs, in order to identify…

Sustained Virologic Response and the Risk of Liver Decompensation in HCV and HIV/HCV Patients

Background: Few studies have evaluated the impact of achieving a sustained virologic response (SVR) on liver-related complications among HIV/hepatitis C virus (HCV)-coinfected patients. Our objective was to assess the effect of SVR on rates of hepatic decompensation in patients with HIV/HCV coinfection and HCV monoinfection. Methodology: We conducted a cohort study among HIV/HCV-coinfected and HCV-monoinfected…

Predicting Risk of ESLD in HIV/HCV Patients for Individualized HCV Therapy Decisions

Background: The optimal time to treat hepatitis C virus (HCV) infection in HIV/HCV-coinfected patients is unclear. Improving the ability to identify patients who are more likely to progress to end-stage liver disease (ESLD) would help determine which patients should be targeted for therapy with direct-acting antiviral agents. We evaluated the ability of routinely collected clinical…

Early Adopters: Correlates of Chemoprophylaxis Use in an Online Sample of US Men Who Have Sex With Men

Background: Although HIV pre-exposure prophylaxis (PrEP) use has been shown to decrease HIVincidence among men who have sex with men (MSM), uptake has not been widespread, and the demographics and behaviors of those who initiated PrEP outside of studies is not well known. Methodology: In August 2013, members of the largest MSM sexual-partner seeking networking…

Prevention of HIV Transmission With Post-Exposure Prophylaxis After Infected-Blood Transfusion

Background: Without intervention, 90% of recipients transfused with HIV-infected blood are expected to become infected. While post-exposure prophylaxis (PEP) is commonly prescribed in the setting of non-occupational HIV exposures, there is very limited evidence documenting efficacy in this setting. We report the successful use of combination PEP following transfusion of HIV infected blood from a…